Polymorphisms in *Plasmodium falciparum* Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for *P. falciparum* Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine

Meera Venkatesan, Nahla B. Gadalla, Kasia Stepniewska, Prabin Dahal, Christian Nsanzabana, Clarissa Moriera, Ric N. Price, Andreas Mårtensson, Philip J. Rosenthal, Grant Dorsey, Colin J. Sutherland, Philippe Guérin, Timothy M. E. Davis, Didier Ménard, Ishag Adam, George Ademowo, Cesar Arze, Frederick N. Baliraine, Nicole Berens-Riha, Anders Björkman, Steffen Bormann, Francesco Checchi, Meghna Desai, Mehul Dhorda, Abdoulaye A. Djimdé, Badria B. El-Sayed, Teferi Esthetu, Frederick Eyase, Catherine Falade, Jean-François Faucher, Gabriele Fröberg, Anastasia Grivoyannis, Sally Hamour, Sandrine Houzé, Jacob Johnson, Erasmus Kamugisha, Simon Kariuki, Jean-René Kiechel, Fred Kironde, Poul-Erik Kofoed, Jacques LeBras, Maja Malmberg, Leah Mwai, Billy Ngasala, Francois Nosten, Samuel L. Nsoby, Alexis Nziila, Mary Oguike, Sabina Dahlström Otienoburu, Bernhards Ogu, Jean-Bosco Ouédraogo, Patrice Piola, Lars Rombo, Birgit Schramm, A. Fabrice Some, Julie Thwing, Johan Ursing, Rina P. M. Wong, Ahmed Zeynudin, Issaka Zongo, Christopher V. Plowe, and Carol Hopkins Sibley for the WWARN AL and ASAQ Molecular Marker Study Group

**Abstract.** Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the *Plasmodium falciparum* chloroquine resistance transporter (*pfcrt*) and *P. falciparum* multidrug resistance 1 (*pfmdr1*) genes are associated with decreased sensitivity to amodiaquine and lumefantrine, but effects of these polymorphisms on therapeutic responses to artemate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients were analyzed to assess relationships between parasite polymorphisms in *pfcrt* and *pfmdr1* and clinically relevant outcomes after treatment with AL or ASAQ. Presence of the *pfmdr1* gene N86 (adjusted hazards ratio = 4.74, 95% confidence interval = 2.29–9.78, *P* < 0.001) and increased *pfmdr1* copy number (adjusted hazards ratio = 6.52, 95% confidence interval = 2.36–17.97, *P* < 0.001) were significant independent risk factors for recrudescence in patients treated with AL. AL and ASAQ exerted opposing selective effects on single-nucleotide polymorphisms in *pfcrt* and *pfmdr1*. Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least *pfcrt* K76T and *pfmdr1* N86Y should now be routine.

**INTRODUCTION**

Recent successes in malaria control have depended on the use of highly efficacious artemisinin combination therapies (ACTs) for first-line treatment of uncomplicated *Plasmodium falciparum* malaria. Adequate clinical and parasitologic cure by ACTs relies on the rapid reduction in parasite biomass by the potent, short-acting artemisinin component and the subsequent elimination of residual parasites by the longer-acting partner drug. The two most commonly used ACTs worldwide are artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ). Polymerase chain reaction (PCR)–adjusted efficacy for both combinations remains high in most regions. However, there have been some reports of decreasing AL cure rates in Africa and Asia, and reports of high levels of treatment failures of ASAQ. Resistance to ACT partner drugs has historically manifested before that of artemisinins, whose short half-lives result in the exposure of residual parasites to sub-therapeutic levels of the partner drug alone. Response to the partner drug is therefore a key component of overall ACT efficacy.

Mutations in the gene encoding the *P. falciparum* chloroquine resistance transporter (*pfcrt*) are associated with chloroquine resistance, a change from lysine to threonine at codon 76 in *pfcrt* predicts responses of parasites to chloroquine. In the presence of *pfcrt* 76T, chloroquine resistance is modulated by point mutations in the gene that encodes the *P. falciparum* multidrug resistance transporter 1 (*pfmdr1*), primarily at codon 86 and 184, 1034, 1042, and 1246. Decreased susceptibility to lumefantrine has been linked to polymorphisms in these two genes. Increased *pfmdr1* copy number, which confers resistance to mefloquine, has also been associated with reduced susceptibility to lumefantrine.

Some studies of amodiaquine have reported reduced *in vivo* response and increased 50% inhibitory concentration values *in vitro*, in association with the presence of *pfmdr1* 86Y and *pfcrt* 76T alleles. Selection of these alleles in recurrent parasites after treatment with amodiaquine alone or in combination with artesunate has been observed in a number of studies.

It has also been suggested that parasites that carry chloroquine-resistant *pfmdr1* alleles may be more susceptible to artesunate in classical *in vitro* assays, an effect that could counteract the increased risk of amodiaquine failure when these drugs are combined in ASAQ.

Currently, AL and ASAQ retain high clinical efficacy with few recrudescence infections, and individual studies generally lack sufficient statistical power to assess the association between parasite genotypes and outcomes of clinical treatment. Such an assessment is a critical step in validating molecular changes in parasite populations as useful markers of early signs of changing parasite susceptibility to lumefantrine or amodiaquine.

To overcome these challenges, individual patient data on *in vivo* antimalarial efficacy and molecular markers of...
P. falciparum from 31 clinical trials were standardized, pooled, and > 7,000 patient responses were analyzed to determine whether patients infected with parasites that carry these polymorphisms are at increased risk of treatment failure. This large data set also provided the opportunity to examine the effects of AL and ASAQ treatment on selection in parasites of particular alleles of pfcr and pfmdr1.

METHODS

Selection and inclusion of data. Prospective clinical efficacy studies of P. falciparum treatment with AL (six-dose regimen) or ASAQ (three-day fixed dose or loose/co-blistered regimen) with a minimum of 28 days of follow-up and genotyping of pfcr and/or pfmdr1 were sought for the analysis. Studies were identified by a systematic PubMed literature review using the search terms (artesunate AND amodiaquine) OR (artemether AND lumefantrine) OR (ACT) AND (pfmdr1 OR pfcr). Abstracts and text were screened to determine whether inclusion criteria were met. Nine unpublished datasets were also solicited and included in the analysis (see Supplemental Table 3). Individual anonymized patient data including baseline characteristics, drug intake, parasite density and temperature were collected. All but one study included parasite genotyping to identify recrudescent infections of P. falciparum, and all studies assessed the presence of pfcr and/or pfmdr1 polymorphisms (single nucleotide polymorphisms (SNPs) and copy number variation) in parasites isolated from patients on day 0. Multiplicity of infection and molecular resistance marker data from other days including the day of microscopic recurrent parasitemia were included but were not a prerequisite for study inclusion. Metadata on study location, study design, drugs, and dosing regimens were also gathered.

A schematic of the patient numbers and overall flow of the study is shown in Figure 1.

Data curation and generation of variables. All data sets were uploaded to the WorldWide Antimalarial Resistance Network repository and standardized by using the WorldWide Antimalarial Resistance Network Data Management and Statistical Analysis Plans (DMSAP).53,54 Outcome status and censoring were defined according to the Clinical DMSAP.53 Parasites that recurred within the follow-up period were classified using World Health Organization guidelines55: microscopically detected infections during follow-up were classified as recurrent; recurrent infections sharing with blood samples taken at day 0 PCR bands in polymorphic merozoite antigens or microsatellite fragment sizes were classified as recrudescent, and recurrent infections not sharing PCR bands or microsatellite fragment sizes with blood samples taken at day 0 were classified as re-infections (new infections). Molecular markers were coded as either single or mixed allele genotypes in the case of SNPs and as mean copy number per sample for copy number polymorphisms. Multi-SNP haplotypes were reconstructed as described in the Molecular DMSAP.56,57

Statistical analysis. All statistical analyses were conducted by using Stata 11 (StataCorp LP, College Station, TX). The primary endpoint was clinical efficacy, defined as the PCR-adjusted risk of P. falciparum recrudescent infections. The cumulative risk of recrudescence at day 28 and day 42 was computed by using survival analysis (Kaplan-Meier estimates [K-M]). Comparisons of K-M survival curves were performed by using log rank tests stratified by study sites.

Multivariable analysis of risk factors associated with PCR-adjusted recrudescence was conducted by using Cox proportional hazards regression models with shared frailty parameters to adjust for site-specific effects. The risk factors that affect

---

**Figure 1.** Patient flow chart for study of parasite risk factors that affect treatment outcomes for *Plasmodium falciparum* malaria after treatment with artemether-lumefantrine (AL) or artesunate-amodiaquine (ASAQ).
the clinical efficacy of AL and ASAQ have been intensively studied in pooled analyses of both ACTs. Sixty-two studies with 14,679 patients treated with AL and 39 studies with 7,652 patients treated with ASAQ were analyzed; these full analyses have been submitted for publication. The univariable and multivariable risk factors identified in those studies are shown in Supplemental Tables 1 and 2. Clinical covariates in the current study were included based on the previous analyses as follows: (lumefantrine or amodiaquine dose, enrolment parasitemia, age category, and ASAQ fixed or co-blistered versus loose formulation (Table 1). Each molecular marker was then added to the model. The proportional hazard assumption was tested based on residuals of Schoenfeld. In the case of non-proportionality, interactions with a categorized time variable based on clinical follow-up intervals (< day 14, days 14–21, 21–28, and > day 28) were used to account for changing effects over time, and neighboring windows with similar effects of genetic covariates as determined by Wald test were merged. Finally, other covariates (transmission intensity, region of sample origin, dose supervision, and fat intake) were included in the model if they improved model fit based on the likelihood ratio test. Multiplicity of infection was only available for 197 and 141 AL and ASAQ patients, respectively, and was excluded from further analysis. The final model was then used to estimate the adjusted hazard ratio for recrudescence in patients who carried parasites with resistant versus sensitive genotypes on day 0. The assumption of proportional hazards was tested separately for the individual covariates in the final multivariable model, and any violations were reported.

In patients who had recurrent parasitemia on or before day 42, changes in pfcr and pfmdr1 alleles between pre-treatment and post-treatment matched pairs of samples was compared by using McNemar’s test. Changes in genotype, rather than presence of a particular allele, were compared between matched pairs to ensure that differences reflected selection rather than underlying differences in allele frequencies among populations. The effect of markers present at the time of recurrence on median time to PCR-adjusted re-infection (new infection) was investigated by using the Wilcoxon Mann-Whitney U test. Competing risk analysis was used to estimate cumulative incidence of PCR-adjusted re-infections with specific genotypes, where recrudescent and re-infections with other genotypes were treated as competing events.

The number of molecular markers used to distinguish recrudescence from re-infection varied from one to three or more loci. The effect of the number of loci genotyped on outcome classification was investigated in a regression model of predictors of recrudescence within all recurrences. No effect of this variable was observed on the number of recrudescent infections identified among recurrences in univariable or multivariable analysis, it was not further investigated.

### RESULTS

Individual patient and linked parasite genotype data from 31 studies were available (Supplemental Table 3). Data from 7,249 patients who were treated with AL (5,003) or ASAQ (2,246) were included in the analysis. Twenty seven studies were published, representing 91% of all published clinical data on AL and ASAQ in which pfcr or pfmdr1 genotypes were determined. Baseline characteristics for patients treated with AL or ASAQ are shown in Supplemental Table 4.

### Clinical efficacy of AL and ASAQ

The estimates of efficacy (defined as risk of PCR-adjusted recrudescence) of AL and ASAQ are shown in Table 2. Of the 5,003 AL patients, 4,763 were followed-up for at least one day and were included in the analysis. Similarly, of the 2,246 ASAQ patients, 2,099 were included. In total, 1,107 patients had recurrent parasitemia after treatment with AL, of which 188 (18%) were classified by PCR as having recrudescent infections. The corresponding figures for ASAQ showed that 484 patients had recurrent parasitemia and 58 (12%) were confirmed as having recrudescent infections. The overall clinical efficacy at day 42 was 94.8% (95% confidence interval [CI] = 94.5–95.5%) in patients treated with AL and 95.1% (95% CI = 93.3–96.7%) in patients treated with ASAQ (Table 2). The proportion of adequate clinical and parasitologic response of ASAQ was significantly higher for the fixed dose and co-blistered tablets (97.0%, 95% CI = 94.4–98.4%) compared with the loose formulation (93.0%, 95% CI = 89.2–95.6) (P = 0.003).

### Baseline prevalence of genetic markers associated with resistance

The baseline prevalence of SNPs in pfcr and pfmdr1 was determined, but not all SNPs were available for all isolates. The most frequently analyzed SNPs were position 76 in pfcr and pfmdr1 alleles were varied by region (Table 3). The pfcr 76T allele (all in the SVMNT haplotype) was almost fixed at 96.4% (81/84) in isolates from Asia (Thailand) and Oceania (Papua New Guinea). In Africa, the only resistant haplotype observed was the CVIET allele. The 76T allele predominated: 67.6% (1,155/1,708) in East Africa and 73.3% (1,354/1,848) in West Africa (Table 3). Amplification of pfmdr1 was seen in 50% (88/176) of isolates from Asia.

#### Table 1

| Treatment and variable | Adjusted HR [95% CI] | P |
|------------------------|----------------------|---|
| **AL** (n = 14,679; 371 recrudescences) | | |
| Age category: ≥ 12 years (reference) | | |
| < 1 | 1.55 (0.86–2.78) | 0.150 |
| 1 to < 5 | 2.38 (1.51–3.75) | < 0.001 |
| 5 to < 12 | 1.39 (0.86–2.23) | 0.160 |
| Enrollment parasite density (log scale) | | |
| Lumefantrine dose (mg/kg) | 1.13 (1.05–1.23) | 0.002 |
| Amodiaquine dose (mg/kg) | 1.00 (0.99–1.01) | 0.860 |
| **ASAQ** (n = 7,652; 220 recrudescences) | | |
| Age category: ≥ 12 years (reference) | | |
| < 1 | 2.20 (1.01–4.78) | 0.047 |
| 1 to < 5 | 2.27 (1.13–4.55) | 0.021 |
| 5 to < 12 | 1.51 (0.72–3.17) | 0.140 |
| Enrollment parasite density (log scale) | | |
| Lumefantrine dose (mg/kg) | 1.50 (1.16–1.93) | 0.002 |
| Amodiaquine dose (mg/kg) | 0.92 (0.82–1.04) | 0.180 |
| Drug formulation: fixed dose (reference) | | |
| Co-blistered | 0.98 (0.41–2.32) | 0.960 |
| Loose | 2.94 (1.58–5.48) | 0.001 |

*Risk factors were selected based upon previous analysis of the same data set (*The effect of dosing strategies on the antimalarial efficacy of artemether-lumefantrine: a pooled analysis of individual patient data* by the WWARN AL Study Group) pre-submission approved at PLoS Medicine, March 28, 2014 and *The Effect of Dosing Strategies on the Therapeutic Efficacy of Artemesine Amodiaquine for uncomplicated malaria: A Pooled Analysis of Individual Patient Data* in preparation). Values in bold are statistically significant. PCR = polymerase chain reaction; HR = hazards ratio; CI = confidence interval; AL = artemether-lumefantrine; ASAQ = amodiaquine-adamquin.
exercised for this genotype, but only in 2.6% (17/659) of isolates from Africa. \textit{Pfmdr1} 86Y was found in 29.2% (66/226) of isolates from Asia/Oceania; in contrast, the 86Y allele was present in 61.1% (1247/2033) of isolates from East Africa and 48.7% (643/1321) of isolates from West Africa.

### Table 2

| Variable | AL | ASAQ fixed dose and co-blistered | ASAQ loose |
|----------|----|---------------------------------|-----------|
| No. at risk | 4,763 | 1,113 | 986 |
| ACPR by group, % (95% CI) | | | |
| Age category, years | | | |
| < 1 | 96.7 (92.7–98.5) | 100 | 85.2 (70.5–93.0) |
| 1 to < 5 | 93.6 (92.0–94.8) | 96.4 (93.2–98.1) | 93.8 (90.0–96.2) |
| 5–12 | 96.3 (94.5–97.5) | 98.8 (91.6–99.8) | 99 (96.1–99.8) |
| ≥ 12 | 95.2 (93.8–96.3) | – | – |
| Region | | | |
| Asia/Oceania | 95.2 (93.8–96.2) | – | – |
| East Africa | 93.8 (92.4–95.0) | – | – |
| West Africa | 96.2 (94.6–97.3) | 100† | 91.2 (88.0–94.7) |
| Overall | 94.8 (94.0–95.5) | 97.0 (94.4–98.4) | 93.0 (89.2–95.6) |

*PCR = polymerase chain reaction; ACPR = adequate clinical and parasitologic response; AL = artemether-lumefantrine; ASAQ = artesunate-amodiaquine; CI = confidence interval.
†Followed-up to day 28.

The SNPs at positions 184 and 1246 showed similar patterns, with \textit{pfmdr1} Y184 and D1246 predominating in all three regions (Table 3). Almost all isolates examined carried the \textit{pfmdr1} S1034 (760/844) and N1042 (1,053/1,064).

### Table 3

Baseline (pre-treatment) prevalence of genetic markers associated with drug resistance*

| Marker | Asia/Oceania | East Africa | West Africa |
|--------|-------------|-------------|-------------|
| \textit{pfcrt} 76 | | | |
| Sample size | 84 | 1,708 | 1,848 |
| K | 3 (4) | 553 (32) | 494 (27) |
| K/T | 2 (2) | 125 (7) | 249 (13) |
| T | 79 (94) | 1,030 (60) | 1,105 (60) |
| \textit{pfcrt} 72–76 | | | |
| Sample size | 84 | 155 | 84 |
| CVMNK | 3 (4) | 37 (24) | 14 (17) |
| CVIET | 0 | 117 (75) | 53 (63) |
| SVMNT | 79 (94) | 0 | 0 |
| Mixed | 2 (2) | 1 (1) | 17 (20) |
| \textit{pfmdr1} 86 | | | |
| Sample size | 226 | 2,033 | 1,321 |
| N | 160 (71) | 759 (37) | 678 (51) |
| N/Y | 0 | 378 (19) | 190 (14) |
| Y | 66 (29) | 896 (44) | 453 (34) |
| \textit{pfmdr1} 184 | | | |
| Sample size | 228 | 1,275 | 686 |
| Y | 183 (80) | 803 (63) | 287 (42) |
| Y/F | 8 (4) | 130 (10) | 77 (11) |
| F | 37 (16) | 342 (27) | 322 (47) |
| \textit{pfmdr1} 1246 | | | |
| Sample size | 77 | 1,017 | 687 |
| D | 67 (87) | 454 (45) | 526 (77) |
| D/Y | 10 (13) | 309 (30) | 86 (13) |
| Y | 0 | 254 (25) | 75 (11) |
| \textit{pfmdr1} 86 + 1246 | | | |
| Sample size | 69 | 1,000 | 685 |
| N D | 12 (17) | 129 (13) | 263 (38) |
| N Y | 0 | 9 (1) | 2 (0) |
| Y D | 50 (72) | 248 (25) | 199 (29) |
| Y Y | 0 | 220 (22) | 71 (10) |
| Mixed | 7 (10) | 394 (39) | 150 (22) |

*Values are no. (%). \textit{pfcrt} = \textit{Plasmodium falciparum} chloroquine resistance transporter gene; \textit{pfmdr1} = \textit{P. falciparum} multidrug resistance 1 (\textit{pfmdr1}) gene.

After controlling for age, baseline parasite density, and total lumefantrine dose (Table 1), the presence of parasites in the initial infection that carried \textit{pfmdr1} N86 (alone or a mixed infection with \textit{pfmdr1} 86Y) was a significant risk factor for recrudescence infection occurring between days 14 and 28 after AL treatment (adjusted hazards ratio [AHR] = 4.74, 95% CI = 2.29–9.78, P < 0.001) (Table 4 and Figure 2A). Region of sample origin was not included as a covariate in the model because it violated the assumption of proportional hazards. The risk associated with presence of \textit{pfmdr1} N86 remained significant when excluding infections with multiple copies of \textit{pfmdr1} (AHR = 3.93, 95% CI = 1.90–8.94, P < 0.001). The region of sample origin interacted significantly with \textit{pfmdr1} N86, showing that the marker had a larger effect in Asia (AHR = 14.06, 95% CI = 4.52–43.74, P < 0.001) than in Africa (AHR = 3.72, 95% CI = 1.77–7.79, P = 0.001). However, this interaction violated the proportional hazards assumption since there were so few samples in Africa that had multiple copies of \textit{pfmdr1}, and this variable was excluded from the final model.

The presence of more than one copy of \textit{pfmdr1} was a significant risk factor for recrudescence occurring between days 14 and 21 after AL treatment (AHR = 5.81, 95% CI = 2.38–14.21, P < 0.001) (Figure 2B). When the effect of region of origin was added to the model, patients with parasites carrying multiple copy numbers of \textit{pfmdr1} were associated with an increased risk of recrudescence before day 14 (AHR = 83.56, 95% CI = 7.43–939.70, P < 0.001) as well as between days 14 and 21 (AHR = 18.54 (95% CI = 7.61–45.19, P < 0.001) (Table 4). The interaction of region with \textit{pfmdr1} copy number could not be investigated because of insufficient multicopy samples from Africa in the model.

When \textit{pfmdr1} N86 and \textit{pfmdr1} copy number were included in the same model, region of sample origin was no longer a significantly predictive covariate in the multivariable analysis or as an interaction term with either genotype. Both markers remained as significant predictors of recrudescence infection, between days 14 and 28 for \textit{pfmdr1} N86 (AHR = 5.98, 95% CI = 1.68–21.36, P = 0.006) and days 14 and 21 for multiple
The genotype of parasites at the time of re-infection provides another metric of their susceptibility to a drug. This analysis indicated that in patients treated with AL, re-infecting parasites carrying pfmdr1 N86, pfmdr1 D1246, or pfcr K76 alleles appeared earlier than those carrying pfmdr1 86Y, pfmdr1 1246Y, or pfcr 76T (Figure 3A). Correspondingly, in patients treated with AL, parasites carrying pfmdr1 N86 had a median time to re-infection of 28 days (interquartile range = 21–35 days) compared with 35 days (interquartile range = 28–42 days) for those with pfmdr1 86Y (P < 0.001). Similar differences in the time to re-infection were observed for patients infected with parasites that carried the pfmdr1 184F (P = 0.008) or pfcr K76 alleles (P = 0.001) compared with pfmdr1 Y184 or pfcr 76T.

In contrast, in patients treated with ASAQ, parasites carrying pfmdr1 86Y, pfmdr1 1246Y, or pfcr 76T appeared earlier after treatment than those carrying pfmdr1 N86, pfmdr1 D1246 or pfcr K76 (Figure 3B). Parasites with pfcr 76T had a median reinfection day of 28 (interquartile range = 21–35) compared with day 37.5 (interquartile range = 28–42) for re-infections after treatment with ASAQ (Table 5).

### Table 4

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|--------------------|-------------------------------|----|
| pfmdr1 86 (n = 2,543; 135 recrudescent infections)* |                               |    |
| pfmdr1 N86 or N/Y |                               |    |
| In recrudescence up to day 14 | 0.79 (0.25–2.54) | 0.694 |
| In recrudescence between days 14 and 28 | **4.74 (2.29–9.78)** | < **0.001** |
| In recrudescence after day 28 | 0.84 (0.43–1.66) | 0.624 |
| Enrollment parasite density (log_{10} – scale) | 1.13 (0.99–1.29) | 0.056 |
| Age category (reference < 1 year) |                               |    |
| 1 to < 5 | 1.05 (0.40–2.75) | 0.922 |
| 5 to < 12 | 0.85 (0.30–2.38) | 0.752 |
| ≥ 12 | 0.77 (0.25–2.36) | 0.647 |
| Lumeferantrine dose (mg/kg) | 0.99 (0.98–1.00) | 0.109 |
| pfmdr1 copy number (n = 808; 73 recrudescent infections)† |                               |    |
| pfmdr1 copy number > 1‡ | 83.56 (7.43–939.70) | < **0.001** |
| In recrudescence up to day 14 | 18.54 (7.61–45.19) | < **0.001** |
| In recrudescence between days 14 and 21 | 0.61 (0.25–1.51) | 0.286 |
| Region (reference Africa) | 5.09 (1.06–24.38) | **0.042** |
| Asia/Oceania |                               |    |
| pfmdr1 86 and copy number (n = 719; 59 recrudescent infections)§ |                               |    |
| pfmdr1 N86 or N/Y |                               |    |
| In recrudescence up to day 14 | 1.00 (0.07–13.64) | 0.997 |
| In recrudescence between days 14 and 28 | **5.98 (1.68–21.36)** | **0.006** |
| In recrudescence after day 28 | 0.51 (0.18–1.47) | 0.21 |
| pfmdr1 copy number > 1 |                               |    |
| In recrudescence up to day 14 | 2.17 (0.16–29.77) | 0.561 |
| In recrudescence between days 14 and 21 | **6.52 (2.36–17.97)** | < **0.001** |
| In recrudescence after day 21 | 0.94 (0.31–2.82) | 0.916 |
| Enrollment parasite density (log_{10} – scale) | 1.08 (0.92–1.28) | 0.248 |
| Age category (reference < 5 years) |                               |    |
| 5 to < 12 | 1.46 (0.59–3.57) | 0.413 |
| ≥ 12 | 0.79 (0.27–2.35) | 0.663 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.95–1.00) | 0.05 |

*Values in bold are statistically significant. PCR = polymerase chain reaction; CI = confidence interval; pfmdr1 = P. falciparum multidrug resistance 1 (pfmdr1) gene.
†Region not included as a covariate or interaction term with pfmdr1 86 genotype because proportional hazards assumption was not met.
‡Sparse data for pfmdr1 copy number in Africa prevented the inclusion of region as an interaction term.
§Region as a covariate and region-genotype interaction terms did not have statistically significant effects in this model.

### Table 5

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.85–1.18) | 0.798 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 0.62 (0.22–1.77) | 0.368 |
| ≥ 12 | 0.56 (0.16–1.93) | 0.359 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.96–1.00) | 0.113 |

### Table 6

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.18–1.47) | 0.21 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 1.46 (0.59–3.57) | 0.413 |
| ≥ 12 | 0.79 (0.27–2.35) | 0.663 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.95–1.00) | 0.05 |

### Table 7

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.85–1.18) | 0.798 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 0.62 (0.22–1.77) | 0.368 |
| ≥ 12 | 0.56 (0.16–1.93) | 0.359 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.96–1.00) | 0.113 |

### Table 8

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.18–1.47) | 0.21 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 1.46 (0.59–3.57) | 0.413 |
| ≥ 12 | 0.79 (0.27–2.35) | 0.663 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.95–1.00) | 0.05 |

### Table 9

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.18–1.47) | 0.21 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 1.46 (0.59–3.57) | 0.413 |
| ≥ 12 | 0.79 (0.27–2.35) | 0.663 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.95–1.00) | 0.05 |

### Table 10

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.18–1.47) | 0.21 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 1.46 (0.59–3.57) | 0.413 |
| ≥ 12 | 0.79 (0.27–2.35) | 0.663 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.95–1.00) | 0.05 |

### Table 11

| Marker and variable | Adjusted hazard ratio (95% CI) | P  |
|-------------------|-------------------------------|----|
| Enrollment parasite density (log_{10} – scale) | 1.00 (0.18–1.47) | 0.21 |
| Age category (reference ≤ 5 years) |                               |    |
| 5 to < 12 | 1.46 (0.59–3.57) | 0.413 |
| ≥ 12 | 0.79 (0.27–2.35) | 0.663 |
| Lumeferantrine dose (mg/kg) | 0.98 (0.95–1.00) | 0.05 |
A small number of recurrent infections (4 for AL and 6 for ASAQ) were not polymerase chain reaction
Plasmodium falciparum
P
K
pfcrt 76
838 Venkatesan and others
recommended 90% efficacy cutoff value for antimalarial drugs.
by World Health Organization–recommended 90% efficacy cutoff value for antimalarial drugs.
Clinical response of patients with parasites that carry A, pfmdr1 86Y (blue) versus 86N or N/Y (red); n = 2,543 patients at risk and
B, pfmdr1 copy number > 1 (yellow) versus single copy (green); n = 808 patients.

![Image](46x423 to 287x724)

**Figure 2.** Polymerase chain reaction–adjusted efficacy as assessed by Kaplan-Meier survival estimates for artemether-lumefantrine (AL) by Plasmodium falciparum multidrug resistance 1 (pfmdr1) genotype of initial parasites. Dotted line indicates World Health Organization–recommended 90% efficacy cutoff value for antimalarial drugs. Clinical response of patients with parasites that carry A, pfmdr1 86Y (blue) versus 86N or N/Y (red); n = 2,543 patients at risk and B, pfmdr1 copy number > 1 (yellow) versus single copy (green); n = 808 patients.

TABLE 5
Selection of pfcrT and pfmdr1 genotypes after treatment with artemether-lumefantrine and artesunate-amodiaquine*

| Marker | Genotype | AL Recurrence | ASAQ Recurrence | AL Recrudescence | ASAQ Recrudescence | AL Re-infection | ASAQ Re-infection |
|--------|----------|---------------|-----------------|------------------|--------------------|-----------------|------------------|
| pfcrT 76 | K → T† | 16% (89/571) 10% (25/257) | 5% (4/73) 20% (7/35) | 17% (82/493) 9% (17/196) |
| | T → K | 30% (171/571) 8% (18/237) | 25% (18/73) 11% (4/35) | 31% (152/493) 7% (14/196) |
| | No change | 54% (311/571) 82% (194/237) | 70% (51/73) 69% (24/35) | 53% (259/493) 84% (165/196) |
| P value | 0.001 | 0.286 | 0.004 (exact) | 0.366 | < 0.001 | 0.590 |
| pfmdr1 86 | N → Y | 13% (95/712) 27% (92/341) | 10% (10/101) 18% (5/28) | 14% (85/609) 28% (87/308) |
| | Y → N | 40% (286/712) 16% (54/341) | 31% (31/101) 14% (4/28) | 42% (255/609) 16% (49/308) |
| | No change | 46% (331/712) 57% (195/341) | 59% (60/101) 68% (19/28) | 44% (269/609) 56% (172/308) |
| P value | 0.001 | 0.002 | 0.001 | 0.739 | 0.001 | 0.001 |
| pfmdr1 1246 | Y → F | 24% (74/311) 12% (37/303) | 20% (14/69) 12% (3/25) | 25% (60/242) 12% (3/24) |
| | F → Y | 16% (51/311) 17% (50/303) | 14% (10/69) 4% (1/25) | 17% (41/242) 18% (49/273) |
| | No change | 60% (186/311) 71% (216/303) | 65% (45/69) 84% (21/25) | 58% (141/242) 70% (190/273) |
| P value | 0.040 | 0.163 | 0.414 | 0.625 | 0.059 | 0.100 |
| pfmdr1 1246 | D → Y | 14% (38/273) 32% (102/317) | 11% (5/44) 39% (11/28) | 15% (33/227) 32% (90/284) |
| | Y → D | 32% (86/273) 19% (60/317) | 30% (13/44) 14% (4/28) | 32% (73/227) 20% (56/284) |
| | No change | 54% (149/273) 49% (155/317) | 59% (26/44) 46% (13/28) | 53% (121/227) 48% (138/284) |
| P value | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| pfmdr1 copy number | 1 → 2 or more | 1% (2/269) | 1% (4/253) | 4% (2/53) | – | 0 |
| | 2 or more → 1 | 1% (3/269) | 2% (1/53) | – | 1% (2/216) | – |
| | No change | 98% (264/269) | 94% (50/53) | – | 99% (214/216) | – |
| P value | 1.000 (exact) | 1.000 (exact) | 0.500 (exact) | – | – | – |

*Values in bold indicate statistically significant selection (P < 0.05) by using McNemar’s paired test. Those marked exact were tested by using the exact distribution for small sample sizes.
†Each category includes all changes from one allele to another. For example, K → T includes K → T, K → K/T, and K/T → T changes.

Our observation that parasites with the pfmdr1 N86, D1246, and pfcrT K76 alleles re-infected patients earlier after AL treatment, and parasites carrying the pfmdr1 86Y, 1246Y, and pfcrT 76I alleles re-infected patients earlier after ASAQ is also congruent with the molecular studies. These differences suggest that parasites with these genotypes can withstand higher drug concentrations compared with parasites that carry the alternative alleles. Recently, Malmberg and others demonstrate this effect quantitatively. After AL treatment, parasites with the pfmdr1 N86/184F/D1246 haplotype were able to re-infect patients whose lumefantrine blood concentrations were 15-fold higher than was the case for parasites carrying the 86Y/Y184/1246Y haplotype, providing a potential pharmacologic explanation for the molecular findings.

**DISCUSSION**

This pooled analysis of data from 31 clinical studies shows clearly that the genotypes of infecting parasites influence the outcome of AL treatment. Patients infected with parasites that carried the pfmdr1 N86 allele or increased pfmdr1 copy number were at significantly greater risk of treatment failure than those whose parasites carried the 86Y allele or a single copy of pfmdr1. Analysis of the clinical outcomes after treatment with ASAQ did not link a particular genotype with treatment failure in this smaller data set. However, it did show clear evidence of selection of particular parasite genotypes. Our findings are consistent with those of previous molecular studies in which changes in the prevalence of the parasite population of particular alleles of pfcrT or pfmdr1 have been documented in response to introduction or increased use of lumefantrine or amodiaquine.
Together, these observations suggest that monitoring shifts to earlier time of re-infection could provide a relatively simple warning of decreasing susceptibility to these drugs, especially if combined with timed measurement of drug concentrations in patients’ blood.

In Southeast Asia, parasites with increased pfmdr1 copy number are common in areas where mefloquine has been intensively deployed, and almost half of the samples in our data set from that region had at least two copies of the gene. Increased pfmdr1 copy number was rarely observed in our large sample of isolates from Africa, populations that have had little exposure to mefloquine. Lumezantrine has a shorter half-life in patients than mefloquine, and may not exert an equivalently strong selection for copy number increase. However, in areas where mefloquine is being introduced, close attention to pfmdr1 copy number is clearly warranted. A recent report of parasites in Ghana with increased pfmdr1 copy number underscores the importance of including this parameter in molecular surveillance.

This study supported the conclusion that parasites with increased copy number of pfmdr1 are also less sensitive to lumezantrine. In Southeast Asia, the amplified alleles almost always carried the N86 allele of pfmdr1. However, this was not the case in the few parasites from Africa in our data set that did have an increased copy number so either of the N86Y alleles of pfmdr1 can apparently be amplified. It is also important to note that increased copy number and the presence of the pfmdr1 N86 allele were independent risk factors for treatment failure in our analysis.

The evidence of strong selection of particular alleles by both drugs in recurrent parasites, coupled with our observation that particular parasite genotypes increase risk of treatment failure, demonstrates that tracking these molecular markers can signal early decreases in susceptibility to lumezantrine or amodiaquine. Both alleles of pfmdr1 N86Y, Y184F, and D1246Y are common in P. falciparum populations in Africa, and pfcr K76 has increased in prevalence in recent years. Thus, changes in the prevalence of these alleles can be a sensitive indicator of selection of parasite populations by AL and ASAQ. In turn, decreasing efficacy of these partner drugs exposes the artemether or artesunate component of the ACT to selective pressure and could facilitate emergence of new foci of resistance to artemisinin, as observed in the Mekong region. The recent identification of a marker correlated with slow response to artemisinin, will also enable molecular assessment of this trend.

Application of these molecular tools is increasingly feasible in the context of clinical trials and in community surveys of populations where AL or ASAQ are heavily used. These approaches can offer cost-effective methods that detect evidence of declines in parasite susceptibility far earlier than before, enabling detailed studies of clinical responses to the drugs in areas of concern. This two-stage approach can provide an opportunity for policy makers to manage emerging
threats of resistance before clinical failure of a drug is manifest and preserve the useful therapeutic life of these valuable antimalarial drugs for as long as possible.

Finally, these results suggest that AL and AS AQ interact with the proteins encoded by pfcr t and pfdmdr1, but the two drugs select alternative alleles. Two recent publications have also demonstrated that piperazine exerts selection pressure on these genes in the same direction as amodiaquine, suggesting that the newer ACT, dihydroartemisinin-piperazine could also function as a counterweight to lume fantrine.

This opposing selection of parasite genotypes by the partner drugs could influence the choice of an ACT in regions with different patterns of pfcr t and pfdmdr1 polymorphisms. For example, if a particular allele is rapidly increasing under intensive use of AL, AS AQ or dihydroartemisinin-piperazine might be introduced to counteract that trend. Concurrent use of two ACTs that exert opposing selective pressures on recurrent parasites could provide a counterbalance and prevent strong directional selection in pfcr t and pfdmdr1, maintaining the overall efficacy of AL and AS AQ for a long period. Despite logistical challenges, the simultaneous use of multiple first line therapies is supported by mathematical models and concurrent availability of AL and AS AQ, as implemented in some countries in West Africa may provide a practical means to test this strategy directly.

Received January 14, 2014. Accepted for publication April 22, 2014.

Published online July 21, 2014.

Note: Supplemental tables appear at www.ajtmh.org.

Financial support: The WorldWide Antimalarial Resistance Network is supported by the Bill and Melinda Gates Foundation.

Disclaimer: The opinions and assertions contained herein are the personal opinions of authors and are not to be construed as reflecting the views of the U.S. Army Medical Research Unit-Kenya or the U.S. Department of Defense.

Authors’ addresses: Meera Venkatesan and Christopher V. Plowe, WorldWide Antimalarial Resistance Network Molecular Module and Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD. Nahla B. Gadalla, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, and Department of Epidemiology, Tropical Medicine Research Institute, Khartoum, Sudan. Kasia Stepienewska, Prabin Dahal, Christian Nsambazana, and Clarissa Moriera, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Ric N. Price, World Wide Antimalarial Resistance Network Centre, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, and Howard Hughes Medical Institute/Center for Vaccine Development. Andreas Mårtensson, Malaria Research and Charles Darwin University, Darwin, Northern Territory, Australia. Andreas Mårtensson, Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Stockholm, Sweden, and Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. Philip J. Rosenthal and Grant Dorsey, Department of Medicine, University of California, San Francisco, San Francisco, CA. Colin J. Sutherland and Mary Oguke, Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. Philippe Guérin, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Timothy M. E. Davis and Gina P. M. Wong, School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital, Nedlands, Western Australia, Australia. Didier Ménard, Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia. Ishag Adam, Faculty of Medicine, University of Khartoum, Khartoum, Sudan. George Ademowo, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria. Cesar Arze, WorldWide Antimalarial Resistance Network Molecular Module and Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD. Frederick N. Baliraine, Department of Medical Research, LeTourneau University, Longview, TX. Ivo Berens-Riha, Department of Infectious Diseases and Tropical Medicine, Ludwig Maximilians University, Munich, Germany. Anders Björkman, Gabrielle Fröberg, Lars Rombo, and Johan Ursing, Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Stockholm, Sweden. Maja Malmberg, formerly, Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Stockholm, Sweden, current Department of Biostatistics and Veterinary Public Health, Section of Virology, Swedish University of Agricultural Sciences, Uppsala, Sweden. Steffen Bornmann, Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, and Department of Microbiology, Magdeburg University School of Medicine, Magdeburg, Germany. Francesco Checchi, Save the Children, Paris, France. Megha Desai and Julie Thwing, Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA. Mehal Dhdora, World Wide Antimalarial Resistance Network Molecular Module, University of Maryland School of Medicine, Baltimore, MD, and Epicentre Uga da Research Base, Mbarara, Uganda. Abdoulaye A. Djimé, Malaria Research and Training Centre, Faculty of Pharmacy, University of Science, Technology and Technologies of Bamako, Bamako, Mali. Badria B. El-Sayed, Department of Epidemiology, Tropical Medicine Research Institute, Khartoum, Sudan. Teferi Eshetu and Ahmed Zeynudin, Department of Medical Laboratory Sciences and Pathology, Medical Parasitology Unit, Jimma University, Jimma, Ethiopia. Frederick Eyase and Bernhard Ogutu, U.S. Army Research Unit-Kenya Walter Reed, Kenya Medical Research Institute Project, Kismu, Kenya. Catherine Falade, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria. Jean-François Faucher, Department of Infectious Diseases, University Medical Center, Besançon, France, and Institut de Recherche pour le Développement, Paris, France. Anastasia Grivoyannis, Department of Medicine, Division of Emergency Medicine, University of Washington, Seattle, WA. Sally Hamour, University College London Centre for Nephrology, Royal Free Hospital, London, United Kingdom. Sandrine Houzé and Jacques Le Bras, Laboratory of Parasitology, Malaria National Reference Centre, Assistance Publique–Hôpitaux de Paris, Bichat Hospital, Paris France, Institut de Recherche pour le Développement, Paris, France. Pintons Troops, Paris, France, and Faculté de Pharmacie, PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France. Jacob Johnson, U.S. Army Medical Research Unit-Kenya, Nairobi, Kenya. Erasmus Kamugisha, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania. Simon Kariuki, Malaria Branch, Kenya Medical Research Institute Centers for Disease Control and Prevention, Kenya. Jean-René Kiechel, Drugs for Neglected Diseases Initiative, Geneva, Switzerland. Fred Kironde, Makerere University College of Health Sciences, Kampala, Uganda, and St. Augustine International University, Kampala, Uganda. Poul-Erik Kofoed, Projecto de Saúde de Bandim, INDEPTH Network, Bissau, Guinea-Bissau and Department of Paediatrics, Kolding Hospital, Kolding, Denmark. Leah Mwai, formerly, Kenya Medical Research Institute/Wel lcome Trust Research Programme, Kilifi, Kenya, currently Division of Translational Therapeutics, Department of Paediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Billy Ngasala, Department of Parasitology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. Frances Nosten, Centre for Tropical Medicine and Malaria Control, University of Oxford, Oxford, United Kingdom, and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Samuel L. Nsobya, Department of Pathology, School of Biomedical Science, Makerere University College of Health Sciences, Kampala, Uganda. Alexis Nziia, formerly, Kenya Medical Research Institute and WorldWide Antimalarial Resistance Network Molecular Module and Institute for Genome Sciences, University of California, San Francisco, San Francisco, CA. Colin J. Sutherland and Mary Oguke, Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. Philip Guérin, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Timothy M. E. Davis and Gina P. M. Wong, School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital, Nedlands, Western Australia, Australia. Didier Ménard, Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia. Ishag Adam, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Bernard Hospital, Paris, France. Jean-Bosco Ouedraogo, A. Fabrice Somé, and Issaka Zongo, Institut de Recherche en Sciences de la Santé, Centre Muraz, Bobo-Dioulasso, Burkina Faso. Patrice Piola, formerly, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, currently, Institut Pasteur du Madagascar, Antananarivo, Madagascar. Birgit Schramm, Episcapte, Paris, France. Carol Hopkins Sibley, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, and Department of Genome Sciences, University of Washington, Seattle, WA.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Bethell DB, Teja-Isavadharm P, Caot XT, Pham TT, Ta TT, Tran TN, Nguyen TT, Pham TP, Kyle D, Day NP, White NJ, 1997. Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 91: 195–198.

2. Na BK, Karbwang J, Thomas CG, Thanavibul A, Sukontason K, Ward SA, Edwards G, 1994. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J Clin Pharmacol 37: 249–253.

3. White NJ, van VM, Ezzet F, 1999. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 37: 105–125.

4. World Health Organization, 2013. World Malaria Report 2013. Available at: http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/. Accessed December 30, 2013.

5. Makanga M, Kruusdoo S, 2009. The clinical efficacy of artemether/lumefantrine (Coartem). Malar J 8 (Suppl 1): S5.

6. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, 2009. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev CD007483.

7. Stover KR, King ST, Robinson J, 2012. Artemether-lumefantrine: an option for malaria. Ann Pharmacother 46: 567–577.

8. Muktar EA, Gadalla NB, El-Zake SE, Mukhtar I, Mansour F.A, Babiker A, El-Sayed BB, 2007. A comparative study on the efficacy of artesunate plus sulfadoxine-pyrimethamine versus artemether-lumefantrine in eastern Sudan. Malar J 6: 92.

9. Siribie M, Diarra A, Tiono AB, Soulama I, Sirima SB, 2012. Efficacy of artemether-lumefantrine in the treatment of uncomplicated malaria in children living in a rural area of Burkina Faso in 2009. Bull Soc Pathol Exot 105: 202–207.

10. Abuaku B, Duah N, Quaye L, Quashie N, Koram K, 2012. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J 11: 188.

11. Ngasala BE, Malmberg M,Carlson AM, Ferreira PE, Petzold MG, Blesborn D, Bergqvist Y, Gil JP, Premji Z, Martensson A, 2011. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J 10: 64.

12. Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, Sokouthea S, Sophorn L, Zhou C, Deng C, Wang Q, Li G, 2011. Randomized trials of artesininin-piperazine, dihydroartemisinin-piperazine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 10: 231.

13. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ, 2005. Amodiaquine alone, amodiaquine-sulfadoxine-pyrimethamine, amodiaquine-artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365: 1474–1480.

14. Martensson A, Stromberg J, Sisowath C, Mesellem MI, Gil JP, Montgomery SM, Olliaro P, Aliu AS, Bjorkman A, 2005. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41: 1092–1098.

15. Thwing J, Odero CO, Odhiambo FO, Otieno KO, Kariuki S, Ord R, Roper C, McMorrow M, Vulule J, Slutsker L, Newman RD, Hamel MJ, Desai M, 2009. In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health 14: 294–300.

16. Hamour S, Melaku Y, Keus K, Wambujo J, Atkin S, Montgomery J, Ford N, Hook C, Checchi F, 2005. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Trans R Soc Trop Med Hyg 99: 548–553.

17. Swarthout TD, van den Brock IV, Kayembe G, Montgomery J, Pota H, Roper C, 2006. Artesunate + amodiaquine and artesunate + sulfadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulfadoxine and pyrimethamine-resistant haplotypes. Trop Med Int Health 11: 1503–1511.

18. Rweyacundo CE, Kareema C, Mugisha V, Erhardt A, Dujanova J, Van OC, Ringwald P, D’Alessandro U, 2004. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health 9: 1091–1098.

19. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su ZX, Wootton JC, Roepe PD, Wellem TE, 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein Pfct and evidence for their role in chloroquine resistance. Mol Cell 6: 861–871.

20. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Dioure Y, Coulibaï D, Dicko A, Su ZX, Nomura T, Fidock DA, Wellem TE, Plowe CV, 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344: 257–263.

21. Djimde AA, Barger B, Kone A, Beavogui AH, Tekete M, Fofana B, Dara A, Maiga H, Dembele D, Toure S, Dama S, Oluogolum D, Sangare CF, Dolo A, Sogoba N, Nimaga K, Kone Y, Doumbo OK, 2010. A molecular map of chloroquine resistance in Mali. FEMS Immunol Med Microbiol 58: 113–118.

22. Babiker HA, Pringle SJ, Abdel-Muhsein A, Mackinnon M, Hunt P, Walliker D, 2001. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcr and the multidrug resistance Gene pfmdr1. J Infect Dis 183: 1535–1538.

23. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G, Aravind L, Cooper RA, Wootton JC, Xiaon M, Su ZX, 2003. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol 49: 977–989.

24. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF, 2000. Pgh1 modulates sensitivity and resistance to multiple anti-malarials in Plasmodium falciparum. Nature 403: 906–909.

25. Sisowath C, Stromberg J, Martensson A, Mesellem M, Obono C, Bjorkman A, Gil JP, 2005. In vivo selection of Plasmodium falciparum pfmdrl 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191: 1014–1017.

26. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey RD, Hamel MJ, Desai M, 2009. Selection of Plasmodium falciparum pfmdrl alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 50: 1893–1895.

27. Sisowath C, Ferreira PE, Bastamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP, 2007. The role of pfmdrl in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 12: 736–742.

28. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL, 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium
falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 51: 991–997.

29. Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, Krishna S, White NJ, Nosten F, Price RN, 2007. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis 195: 134–141.

30. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse O, Ouedraogo JB, Rosenthal PJ, 2010. Selection of known Plasmodium falciparum resistance-mediated polymorphisms by arteether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 54: 1949–1954.

31. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, Gadalla A, Mansour F, Warhurst D, El-Sayed BB, Sutherland CJ, 2011. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with arteether-lumefantrine. Antimicrob Agents Chemother 55: 5408–5411.

32. Griyovannis A, Niangaly M, Traore OB, Kodio A, Traore K, Tolo Y, Dembele A, Traore A, Bamadio A, Traore ZI, Sanogo K, Sissoko M, Sagara I, Djimde AA, Doumbo OK, 2010. In vivo selection of Plasmodium falciparum pfcr K76 and pfmdr1 N86 alleles by arteether-lumefantrine in Mali. Am Soc Trop Med Hyg 59: 328.

33. Malmberg M, Ferreira PE, Tarning J, Ursing J, Nosten F, 2013. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis 207: 842–847.

34. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagulang R, Nair S, Bashir S, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F, 2006. Molecular and pharmacological determinants of the therapeutic response to artesunate-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 42: 1570–1577.

35. Happi CT, Gbotosho GO, Folain OA, Some AF, Sere YY, Dokomajilar C, Zongo I, Rosenthal PJ, 2007. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by arteether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 53: 888–895.

36. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Ouedraogo JB, Ringwald P, Aroney F, 2009. Pfmdr1 copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 8: 11.

37. Munthim M, Khosinithithikul R, Sitthichot N, Suwandittakul N, Wattanaveeradje V, Ward SA, Na-Bangchang K, 2010. Association between the pfmdr1 gene and in vivo arteether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Am J Trop Med Hyg 83: 1005–1009.

38. Simpson JA, Jansen KM, Anderson TJ, Zaloumis S, Nair S, Woodrow C, White NJ, Nosten F, Price RN, 2013. Nonlinear mixed-effects modelling of in vivo drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum. PLoS ONE 8: e69505.

39. Ochong EO, van den Broek IV, Keus K, Nzila A, 2003. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 69: 184–187.

40. Happi CT, Gbotosho GO, Folain OA, Bolaji OM, Somunni A, Kyle DE, Milhou S, Wirth DF, Oduola AM, 2006. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg 75: 155–161.

41. Tinto H, Guékouni L, Zongo I, Guiguemde RT, D’Alessandro U, Ouedraogo JB, 2008. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health 13: 238–240.

42. Cheever DW, Holmgren G, Murillo C, Higuita JC, Bjorkman A, Gil JP, Osorio L, 2007. Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Am J Trop Med Hyg 77: 1034–1038.

43. Folarin OA, Bustamante C, Gbotosho GO, Somunni A, Zalis MG, Oduola AM, Happi CT, 2011. In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria. Acta Trop 120: 224–230.

44. Holmgren G, Hamrin J, Svard J, Martinsson A, Gil JP, Bjorkman A, 2007. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol 7: 562–569.

45. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Oboonyo CO, Bjorkman A, 2006. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol 6: 309–314.

46. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Sama S, Ouelouogou D, Dicko A, Doumbo OK, 2008. Efficiency, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 78: 455–461.

47. Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt FP, 2010. Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Acta Trop 114: 63–66.

48. Duraisingham MT, Drakeley CJ, Muller O, Bailey R, Snouguen G, Tarrett GA, Greenwood BM, Warhurst DC, 1997. Evidence for selection of the tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitol 114: 205–211.

49. Duraisingham MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC, 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 106: 223–232.

50. WWARN, 2012. Clinical Module: Data Management and Statistical Analysis Plan. Version 1.2. Available at: http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf. Accessed March 31, 2014.

51. WWARN, 2012. Statistical Analysis Plan AL Dose Impact Study Group Version 1.9. Available at: http://www.wwarn.org/sites/default/files/ALDoseImpactStudyGroupSAP.pdf. Accessed March 31, 2014.

52. World Health Organization, 2008. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva: World Health Organization.

53. WWARN, 2012. Molecular Module: Data Management and Statistical Analysis Plan Version 1.0. Available at: http://www.wwarn.org/sites/default/files/MolecularDMSAP.pdf. Accessed March 31, 2014.

54. Choudhury J, 2002. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 21: 1129–1144.
60. Ezzet F, van Vudt M, Nosten F, Looareesuwan S, White NJ. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 44: 697–704.

61. Duah N, Matrevi S, de Souza D, Binnah D, Tamakloe M, Opoku V, Onwona C, Narh C, Quashie N, Abuaku B, Duplessis C, Kronmann K, Koram K. 2013. Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malar J 12: 377.

62. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR. 2003. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 47: 2418–2423.

63. Aricey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chou CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotti O, Ringwald P, Le Bras J, Berry A, Barale J-C, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505: 50–55.

64. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on P. falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 210: 344–353.

65. Taylor SM, Juliano JJ. 2014. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. J Infect Dis 210: 335–337.

66. Boni MF, Smith DL, Laxminarayan R. 2008. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA 105: 14216–14221.

67. Shretta R. 2008. Operational Challenges of Implementing Multiple First-Line Therapies for Malaria in Endemic Countries. Arlington, VA: Management Sciences for Health.

68. Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB. 2011. Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases? Parasitol. 138: 1459–1468.